Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France

被引：0

作者：

Perol, M. ^{[1
]}

Filleron, T. ^{[2
]}

Quantin, X. ^{[3
]}

Chouaid, C. ^{[4
]}

Valette, C. Audigier ^{[5
]}

Lena, H. ^{[6
]}

Kaderbhai, C. ^{[7
]}

Fabre, C. ^{[8
]}

Santorelli, M. ^{[9
]}

Bensimon, L. ^{[10
]}

Burke, T. ^{[11
]}

Couch, D. ^{[12
]}

Nguyen, E. ^{[12
]}

Courtinard, C. ^{[12
]}

机构：

[1] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[2] Ctr Claudius Regaud, Biostat, Toulouse, France

[3] ICM Reg Canc Inst Montpellier, Montpellier, France

[4] CH Intercommunal Creteil, Creteil, France

[5] Hop St Musse, Toulon, France

[6] CHU Pontchaillou, Rennes, France

[7] Ctr Georges Francois Leclerc, Dijon, France

[8] IQVIA Co France, Capionis, Courbevoie, France

[9] Merck & Co Inc, Rahway, NJ USA

[10] MSD France, Dir Ass Evaluat Med Econ & Epidemiol, Puteaux La Defense, France

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] UNICANCER, Data Off, Paris, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

109P

引用

页码：S757 / S758

页数：2

共 50 条

[41] Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001) [J].

Kitamura, Yasuo ;

Mizugaki, Hidenori ;

Ikezawa, Yasuyuki ;

Morita, Ryo ;

Tateishi, Kazunari ;

Yokoo, Keiki ;

Sumi, Toshiyuki ;

Kikuchi, Hajime ;

Nakamura, Atsushi ;

Kobayashi, Maki ;

Aso, Mari ;

Kimura, Nozomu ;

Yoshiike, Fumiaki ;

Furuta, Megumi ;

Tanaka, Hisashi ;

Sekikawa, Motoki ;

Hachiya, Tsutomu ;

Nakamura, Keiichi ;

Oizumi, Satoshi .

ANNALS OF ONCOLOGY, 2022, 33 :S524-S524

[42] Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001) [J].

Nakamura, A. ;

Mizugaki, H. ;

Ikezawa, Y. ;

Morita, R. ;

Tateishi, K. ;

Yokoo, K. ;

Sumi, T. ;

Kikuchi, H. ;

Kitamura, Y. ;

Morita, M. ;

Aso, M. ;

Tsukita, Y. ;

Yoshiike, F. ;

Furuta, M. ;

Tanaka, H. ;

Sekikawa, M. ;

Hachiya, T. ;

Nakamura, K. ;

Yokouchi, H. .

ANNALS OF ONCOLOGY, 2021, 32 :S1008-S1008

[43] Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids [J].

Frost, Nikolaj ;

Kollmeier, Jens ;

Misch, Daniel ;

Vollbrecht, Claudia ;

Grah, Christian ;

Matthes, Burkhard ;

Pultermann, Dennis ;

Olive, Elisabeth ;

Raspe, Matthias ;

Ochsenreither, Sebastian ;

von Laffert, Maximilian ;

Suttorp, Norbert ;

Witzenrath, Martin ;

Grohe, Christian .

CLINICAL LUNG CANCER, 2021, 22 (05) :411-422

[44] Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50% [J].

Brahmer, J. ;

Rodriguez-Abreu, D. ;

Robinson, A. ;

Hui, R. ;

Csoszi, T. ;

Fulop, A. ;

Gottfried, M. ;

Peled, N. ;

Tafreshi, A. ;

Cuffe, S. ;

O'Brien, M. ;

Rao, S. ;

Hotta, K. ;

Riccio, A. ;

Yang, J. ;

Pietanza, M. C. ;

Reck, M. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1793-S1794

[45] Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS >=550%, treatment-naive NSCLC [J].

Satouchi, Miyako ;

Hotta, Katsuyuki ;

Nosaki, Kaname ;

Takahashi, Toshiaki ;

Nakagawa, Kazuhiko ;

Aoe, Keisuke ;

Noguchi, Kazuo ;

Shimamoto, Takashi ;

Rangwala, Reshma ;

Brahmer, Julie .

ANNALS OF ONCOLOGY, 2017, 28 :73-73

[46] PD-1/PD-L1 inhibitors monotherapy vs. combination therapy in elderly advanced NSCLC: a real-world study and nomogram for survival prognosis [J].

Mao, Yunye ;

Wang, An ;

Ge, Xiangwei ;

Zhai, Jinzhao ;

Hu, Yi ;

Wang, Jinliang .

BMC PULMONARY MEDICINE, 2025, 25 (01)

[47] Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy [J].

Pisapia, Pasquale ;

Iaccarino, Antonino ;

De Luca, Caterina ;

Acanfora, Gennaro ;

Bellevicine, Claudio ;

Bianco, Roberto ;

Daniele, Bruno ;

Ciampi, Luisa ;

De Felice, Marco ;

Fabozzi, Teresa ;

Formisano, Luigi ;

Giordano, Pasqualina ;

Gridelli, Cesare ;

Ianniello, Giovanni Pietro ;

Libroia, Annamaria ;

Maione, Paolo ;

Nacchio, Mariantonia ;

Pagni, Fabio ;

Palmieri, Giovanna ;

Pepe, Francesco ;

Russo, Gianluca ;

Salatiello, Maria ;

Santaniello, Antonio ;

Scamarcio, Rachele ;

Seminati, Davide ;

Troia, Michele ;

Troncone, Giancarlo ;

Vigliar, Elena ;

Malapelle, Umberto .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)

[48] Real-World Treatment Patterns and Sequencing of Immunotherapy and Chemotherapy Based on PD-L1 TPS in European Patients With mNSCLC [J].

Gower, M. ;

Janowicz, E. ;

Anderson, D. ;

Capart, P. ;

Stoyanov, N. ;

Nguyen, B. ;

Combest, A. ;

Ognar, R. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S328-S328

[49] Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater [J].

Tambo, Yuichi ;

Sone, Takashi ;

Shibata, Kazuhiko ;

Nishi, Kouichi ;

Shirasaki, Hiroki ;

Yoneda, Taro ;

Araya, Tomoyuki ;

Kase, Kazumasa ;

Nishikawa, Shingo ;

Kimura, Hideharu ;

Kasahara, Kazuo .

ANNALS OF ONCOLOGY, 2021, 32 :S313-S313

[50] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma [J].

Ellebaek, Eva ;

Khan, Shawez ;

Bastholt, Lars ;

Schmidt, Henrik ;

Haslund, Charlotte Aaquist ;

Donia, Marco ;

Svane, Inge Marie .

EUROPEAN JOURNAL OF CANCER, 2024, 198

← 1 2 3 4 5 →

Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS&gt;50%) metastatic NSCLC in France

Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France